The ‘Biologics Fill / Finish Service Providers, 2019-2030′

January 7, 2021

To order this detailed 480+ page report, please visit this link


Key Inclusions

  • A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).
  • A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
  • Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.

The report features inputs from a number of eminent industry stakeholders, according to whom, “Currently, majority of biologics are being filled in vials, however, the scenario is likely to change in the future due to the growing demand and preference for self-administration devices.” The report features detailed transcripts of discussions held with the following experts:

  • Ales Sima, Business Development Manager, oncomed manufacturing
  • Gregor Kawaletz, Chief Commercial Officer, IDT Biologika
  • Jos Vergeest, International Business Developer, HALIX
  • Purushottam Singnurkar, Research Director and Head of Formulation Development, Syngene International


To request sample pages, please visit this link


You may also be interested in the following titles:

  1. Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030
  2. Medical Device Contract Manufacturing Market, 2019-2030
  3. Elastomeric Closure Components Market For Vials, Cartridges and Syringes, 2019-2030: Focus on Caps, Needle Shields, Plungers, Stoppers, Seals, Tip Caps and Other Closures
  4. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030
  5. Patient Recruitment and Retention Services Market, 2019-2030


Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

Article Categories:

Leave a Comment